Corbus Pharmaceuticals Holdings, Inc.(CRBP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $36.1M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CRBP Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Corbus Pharmaceuticals Holdings, Inc. (CRBP), a Healthcare sector company. CRBP is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $36.1m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Corbus Pharmaceuticals Holdings, Inc. reports net income of $-35.0M, free cash flow of $-29.6M. Top institutional holders of CRBP by reported 13-F value include Cormorant Asset Management, ORBIMED ADVISORS, BlackRock, based on the most recent SEC filings. CRBP trades on the Nasdaq exchange and files with the SEC under CIK 1595097. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRBP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Corbus Pharmaceuticals Holdings, Inc. directly from SEC EDGAR. Corbus Pharmaceuticals Holdings, Inc.'s 13F Pro composite quality score has ranged between 4 and 28 since 2021, currently 4.2 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.
Net Income
Q2 2026
$-35.0M
Free Cash Flow
Q2 2026
$-29.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-95.3% YoYOperating Income
-75.1% YoYEPS (Diluted)
-60.3% YoYTotal Assets
+7.9% YoYTotal Debt
Op. Cash Flow
-54.3% YoYFree Cash Flow
-54.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 -100.0% | $881.7K -77.6% | $3.9M |
| Net Income | $-78.5M -95.3% | $-40.2M +9.9% | $-44.6M -5.3% | $-42.3M +7.2% | $-45.6M +59.0% | $-111.3M |
| Operating Income | $-85.3M -75.1% | $-48.7M -8.1% | $-45.1M -13.2% | $-39.8M +28.9% | $-56.0M +54.4% | $-122.8M |
| EPS (Diluted) | $-5.90 -60.3% | $-3.68 +64.3% | $-10.31 -1.6% | $-10.15 +9.0% | $-11.15 | — |
| Total Assets | $168.2M +7.9% | $155.9M +451.4% | $28.3M -57.4% | $66.3M -38.4% | $107.7M +5.3% | $102.3M |
| Total Debt | — | — | $33.8M +38.6% | $24.4M +0.4% | $24.3M +14.6% | $21.2M |
| Operating Cash Flow | $-64.5M -54.3% | $-41.8M -15.8% | $-36.1M +3.8% | $-37.5M +22.1% | $-48.2M +51.7% | $-99.7M |
| Free Cash Flow | $-64.5M -54.3% | $-41.8M -15.8% | $-36.1M +3.9% | $-37.6M +22.1% | $-48.2M +51.8% | $-100.2M |
Get alerted when CRBP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Corbus Pharmaceuticals Holdings, Inc. including:
Top Institutional Holders of CRBP
Cormorant Asset Management, LP
$22.0M2,344,971 shORBIMED ADVISORS LLC
$16.3M1,737,287 shBlackRock, Inc.
$12.5M1,331,135 shabrdn plc
$12.4M1,321,750 shVANGUARD CAPITAL MANAGEMENT LLC
$7.1M760,940 shJones Hill Capital LP
$6.1M653,572 shProsight Management, LP
$6.1M650,000 shDIADEMA PARTNERS LP
$5.9M633,800 shCaption Management, LLC
$5.4M572,300 shStonepine Capital Management, LLC
$4.0M425,000 sh
| Fund | Value | Shares |
|---|---|---|
| Cormorant Asset Management, LP | $22.0M | 2,344,971 |
| ORBIMED ADVISORS LLC | $16.3M | 1,737,287 |
| BlackRock, Inc. | $12.5M | 1,331,135 |
| abrdn plc | $12.4M | 1,321,750 |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.1M | 760,940 |
| Jones Hill Capital LP | $6.1M | 653,572 |
| Prosight Management, LP | $6.1M | 650,000 |
| DIADEMA PARTNERS LP | $5.9M | 633,800 |
| Caption Management, LLC | $5.4M | 572,300 |
| Stonepine Capital Management, LLC | $4.0M | 425,000 |
More Healthcare Companies
View all Healthcare →Put CRBP on your watchlist
Track score changes the day Corbus Pharmaceuticals Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CRBP a good stock to buy?
13F Pro's AI-powered analysis of Corbus Pharmaceuticals Holdings, Inc. (CRBP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRBP are available on the CRBP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CRBP is classified as a small company.
Which hedge funds own CRBP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRBP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Corbus Pharmaceuticals Holdings, Inc.'s investment landscape.